

Daniel Tak Mao Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4069104/publications.pdf>

Version: 2024-02-01

209
papers

10,588
citations

46984

47
h-index

39638

94
g-index

266
all docs

266
docs citations

266
times ranked

9930
citing authors

#	ARTICLE	IF	CITATIONS
1	Efficacy of Mycophenolate Mofetil in Patients with Diffuse Proliferative Lupus Nephritis. <i>New England Journal of Medicine</i> , 2000, 343, 1156-1162.	13.9	905
2	KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, S1-S276.	2.6	782
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.5	759
4	Genome-Wide Association Study in Asian Populations Identifies Variants in ETS1 and WDFY4 Associated with Systemic Lupus Erythematosus. <i>PLoS Genetics</i> , 2010, 6, e1000841.	1.5	378
5	Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 432.	3.8	376
6	Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases. <i>Kidney International</i> , 2021, 100, 753-779.	2.6	325
7	Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. <i>Lancet Diabetes and Endocrinology</i> , 2019, 7, 128-139.	5.5	223
8	Survival analysis and causes of mortality in patients with lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2012, 27, 3248-3254.	0.4	222
9	Roxadustat (FG-4592). <i>Journal of the American Society of Nephrology: JASN</i> , 2016, 27, 1225-1233.	3.0	216
10	Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. <i>Cell</i> , 2021, 184, 2212-2228.e12.	13.5	216
11	Meta-analysis Followed by Replication Identifies Loci in or near CDKN1B, TET3, CD80, DRAM1, and ARID5B as Associated with Systemic Lupus Erythematosus in Asians. <i>American Journal of Human Genetics</i> , 2013, 92, 41-51.	2.6	184
12	Prevalence of Hepatitis C Virus Infection in Hemodialysis Patients: A Longitudinal Study Comparing the Results of RNA and Antibody Assays. <i>Hepatology</i> , 1993, 17, 5-8.	3.6	180
13	Pathophysiological Changes to the Peritoneal Membrane during PD-Related Peritonitis: The Role of Mesothelial Cells. <i>Mediators of Inflammation</i> , 2012, 2012, 1-21.	1.4	178
14	DNA methylation and mRNA and microRNA expression of SLE CD4+ T cells correlate with disease phenotype. <i>Journal of Autoimmunity</i> , 2014, 54, 127-136.	3.0	172
15	Preemptive lamivudine therapy based on HBV DNA level in HBsAg-positive kidney allograft recipients. <i>Hepatology</i> , 2002, 36, 1246-1252.	3.6	151
16	Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. <i>Lupus</i> , 2005, 14, 265-272.	0.8	141
17	Changes of cytokine profiles during peritonitis in patients on continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2000, 35, 644-652.	2.1	139
18	Anti-dsDNA Antibodies Bind to Mesangial Annexin II in Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 1912-1927.	3.0	136

#	ARTICLE	IF	CITATIONS
19	Mechanisms of Kidney Injury in Lupus Nephritis – the Role of Anti-dsDNA Antibodies. <i>Frontiers in Immunology</i> , 2015, 6, 475.	2.2	112
20	ITGAM is associated with disease susceptibility and renal nephritis of systemic lupus erythematosus in Hong Kong Chinese and Thai. <i>Human Molecular Genetics</i> , 2009, 18, 2063-2070.	1.4	104
21	Anti-DNA antibodies in the pathogenesis of lupus nephritis – The emerging mechanisms. <i>Autoimmunity Reviews</i> , 2008, 7, 317-321.	2.5	103
22	Effect of Oral Methylprednisolone on Decline in Kidney Function or Kidney Failure in Patients With IgA Nephropathy. <i>JAMA - Journal of the American Medical Association</i> , 2022, 327, 1888.	3.8	103
23	B Cell Abnormalities in Systemic Lupus Erythematosus and Lupus Nephritis – Role in Pathogenesis and Effect of Immunosuppressive Treatments. <i>International Journal of Molecular Sciences</i> , 2019, 20, 6231.	1.8	88
24	ELF1 is associated with systemic lupus erythematosus in Asian populations. <i>Human Molecular Genetics</i> , 2011, 20, 601-607.	1.4	78
25	Treatment of severe lupus nephritis: the new horizon. <i>Nature Reviews Nephrology</i> , 2015, 11, 46-61.	4.1	78
26	Autoantibodies and Resident Renal Cells in the Pathogenesis of Lupus Nephritis: Getting to Know the Unknown. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-13.	3.3	76
27	Risks and Outcomes of Peritonitis after Flexible Colonoscopy in CAPD Patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 560-564.	1.1	74
28	Rapamycin attenuates the severity of established nephritis in lupus-prone NZB/W F1 mice. <i>Nephrology Dialysis Transplantation</i> , 2008, 23, 2768-2776.	0.4	73
29	Effect of Human Anti-DNA Antibodies on Proximal Renal Tubular Epithelial Cell Cytokine Expression: Implications on Tubulointerstitial Inflammation in Lupus Nephritis. <i>Journal of the American Society of Nephrology: JASN</i> , 2005, 16, 3281-3294.	3.0	72
30	Lupus Nephritis in Asia: Clinical Features and Management. <i>Kidney Diseases (Basel, Switzerland)</i> , 2015, 1, 100-109.	1.2	67
31	Pilot 24-month study to compare mycophenolate mofetil and tacrolimus in the treatment of membranous lupus nephritis with nephrotic syndrome. <i>Nephrology</i> , 2012, 17, 352-357.	0.7	66
32	Roxadustat for CKD-related Anemia in Non-dialysis Patients. <i>Kidney International Reports</i> , 2021, 6, 624-635.	0.4	65
33	Tuberculosis infection in Chinese patients undergoing continuous ambulatory peritoneal dialysis. <i>American Journal of Kidney Diseases</i> , 2001, 38, 1055-1060.	2.1	64
34	Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndrome. <i>Nephrology</i> , 2007, 12, 576-581.	0.7	64
35	Increased expression of TLR2 in CD4 ⁺ T cells from SLE patients enhances immune reactivity and promotes IL-17 expression through histone modifications. <i>European Journal of Immunology</i> , 2015, 45, 2683-2693.	1.6	63
36	Intrinsic Cells: Mesothelial Cells – Central Players in Regulating Inflammation and Resolution. <i>Peritoneal Dialysis International</i> , 2009, 29, 21-27.	1.1	61

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcome of Renal Transplant Recipients With Chronic Hepatitis B Infectionâ€”Impact of Antiviral Treatments. <i>Transplantation</i> , 2010, 90, 325-330.	0.5	59
38	Overview of lupus nephritis management guidelines and perspective from <scp>A</scp>sia. <i>Nephrology</i> , 2014, 19, 11-20.	0.7	59
39	Enhanced Psychosocial Support for Caregiver Burden for Patients With Chronic Kidney Failure Choosing Not to Be Treated by Dialysis or Transplantation: A Pilot Randomized Controlled Trial. <i>American Journal of Kidney Diseases</i> , 2016, 67, 585-592.	2.1	59
40	Glucose degradation products downregulate ZO-1 expression in human peritoneal mesothelial cells: the role of VEGF. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 1336-1349.	0.4	55
41	Recent knowledge on the pathophysiology of septic acute kidney injury: A narrative review. <i>Journal of Critical Care</i> , 2016, 31, 82-89.	1.0	54
42	Anti-dsDNA antibodies and resident renal cells â€” Their putative roles in pathogenesis of renal lesions in lupus nephritis. <i>Clinical Immunology</i> , 2017, 185, 40-50.	1.4	54
43	Anti-dsDNA antibody induction of protein kinase C phosphorylation and fibronectin synthesis in human and murine lupus and the effect of mycophenolic acid. <i>Arthritis and Rheumatism</i> , 2009, 60, 2071-2082.	6.7	53
44	Peritoneal mesothelial cell culture and biology. <i>Peritoneal Dialysis International</i> , 2006, 26, 162-73.	1.1	53
45	Lupus Nephritis. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2013, 8, 147-153.	2.2	50
46	Hepatitis B and Renal Disease. <i>Current Hepatitis Reports</i> , 2010, 9, 99-105.	0.3	49
47	Long-term data on corticosteroids and mycophenolate mofetil treatment in lupus nephritis. <i>Rheumatology</i> , 2013, 52, 480-486.	0.9	49
48	Safety, pharmacokinetics and pharmacodynamics of AMG 811, an anti-interferon- β monoclonal antibody, in SLE subjects without or with lupus nephritis. <i>Lupus Science and Medicine</i> , 2017, 4, e000226.	1.1	49
49	Longterm Data on Sirolimus Treatment in Patients with Lupus Nephritis. <i>Journal of Rheumatology</i> , 2018, 45, 1663-1670.	1.0	48
50	Emodin ameliorates glucose-induced matrix synthesis in human peritoneal mesothelial cells. <i>Kidney International</i> , 2003, 64, 519-533.	2.6	46
51	E4BP4 overexpression: A protective mechanism in CD4+ T cells from SLE patients. <i>Journal of Autoimmunity</i> , 2013, 41, 152-160.	3.0	46
52	Cellular Cholesterol Transport Proteins in Diabetic Nephropathy. <i>PLoS ONE</i> , 2014, 9, e105787.	1.1	46
53	Syndecan-4 up-regulation in proliferative renal disease is related to microfilament organization. <i>FASEB Journal</i> , 2001, 15, 1631-1633.	0.2	45
54	The effect of mycophenolic acid on epigenetic modifications in lupus CD4+T cells. <i>Clinical Immunology</i> , 2015, 158, 67-76.	1.4	45

#	ARTICLE	IF	CITATIONS
55	Peripheral whole blood FOXP3 TSDR methylation: a potential marker in severity assessment of autoimmune diseases and chronic infections. <i>Immunological Investigations</i> , 2015, 44, 126-136.	1.0	45
56	Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. <i>Arthritis and Rheumatology</i> , 2019, 71, 411-419.	2.9	45
57	Anti-dsDNA antibody induces soluble fibronectin secretion by proximal renal tubular epithelial cells and downstream increase of TGF- β 1 and collagen synthesis. <i>Journal of Autoimmunity</i> , 2015, 58, 111-122.	3.0	43
58	Pathophysiology of the Peritoneal Membrane during Peritoneal Dialysis: The Role of Hyaluronan. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-11.	3.0	42
59	Long-term data on tacrolimus treatment in lupus nephritis. <i>Rheumatology</i> , 2014, 53, 2232-2237.	0.9	42
60	Septic acute kidney injury in critically ill patients – a single-center study on its incidence, clinical characteristics, and outcome predictors. <i>Renal Failure</i> , 2016, 38, 706-716.	0.8	42
61	mTOR Inhibition and Kidney Diseases. <i>Transplantation</i> , 2018, 102, S32-S40.	0.5	42
62	Blocking Stemness and Metastatic Properties of Ovarian Cancer Cells by Targeting p70S6K with Dendrimer Nanovector-Based siRNA Delivery. <i>Molecular Therapy</i> , 2018, 26, 70-83.	3.7	42
63	Proliferation signal inhibitors in the treatment of lupus nephritis: Preliminary experience. <i>Nephrology</i> , 2012, 17, 676-680.	0.7	41
64	Relationship between autoantibody clustering and clinical subsets in SLE: cluster and association analyses in Hong Kong Chinese. <i>Rheumatology</i> , 2013, 52, 337-345.	0.9	41
65	Mediators of Inflammation and Their Effect on Resident Renal Cells: Implications in Lupus Nephritis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-10.	3.3	40
66	Genome-Wide DNA Methylation Analysis of Chinese Patients with Systemic Lupus Erythematosus Identified Hypomethylation in Genes Related to the Type I Interferon Pathway. <i>PLoS ONE</i> , 2017, 12, e0169553.	1.1	40
67	Immunogenicity of Intradermal Hepatitis B Vaccination in Renal Transplant Recipients. <i>American Journal of Transplantation</i> , 2002, 2, 965-969.	2.6	38
68	Effect of rapamycin on renal ischemia-reperfusion injury in mice. <i>Transplant International</i> , 2006, 19, 834-839.	0.8	38
69	A Possible Role of HMGB1 in DNA Demethylation in CD4 ⁺ T Cells from Patients with Systemic Lupus Erythematosus. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-5.	3.3	37
70	Longterm Data on Disease Flares in Patients with Proliferative Lupus Nephritis in Recent Years. <i>Journal of Rheumatology</i> , 2017, 44, 1375-1383.	1.0	37
71	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.5	37
72	Elevated glucose induction of thrombospondin-1 up-regulates fibronectin synthesis in proximal renal tubular epithelial cells through TGF- β 1 dependent and TGF- β 1 independent pathways. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 1504-1513.	0.4	36

#	ARTICLE	IF	CITATIONS
73	A Combination of Biocompatible Peritoneal Dialysis Solutions and Residual Renal Function, Peritoneal Transport, and Inflammation Markers: A Randomized Clinical Trial. <i>American Journal of Kidney Diseases</i> , 2012, 60, 966-975.	2.1	36
74	Sulodexide Decreases Albuminuria and Regulates Matrix Protein Accumulation in C57BL/6 Mice with Streptozotocin-Induced Type I Diabetic Nephropathy. <i>PLoS ONE</i> , 2013, 8, e54501.	1.1	36
75	Cost Comparison Between Mycophenolate Mofetil and Cyclophosphamide-Azathioprine in the Treatment of Lupus Nephritis. <i>Journal of Rheumatology</i> , 2009, 36, 76-81.	1.0	35
76	Meta-analysis of GWAS on two Chinese populations followed by replication identifies novel genetic variants on the X chromosome associated with systemic lupus erythematosus. <i>Human Molecular Genetics</i> , 2015, 24, 274-284.	1.4	35
77	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.5	35
78	Comparison of the Second-Generation Digene Hybrid Capture Assay with the Branched-DNA Assay for Measurement of Hepatitis B Virus DNA in Serum. <i>Journal of Clinical Microbiology</i> , 1999, 37, 2461-2465.	1.8	35
79	Intrinsic cells: mesothelial cells – central players in regulating inflammation and resolution. <i>Peritoneal Dialysis International</i> , 2009, 29 Suppl 2, S21-7.	1.1	35
80	Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. <i>Nephrology</i> , 2007, 12, 11-17.	0.7	34
81	Overview of lupus nephritis management guidelines and perspective from Asia. <i>International Journal of Rheumatic Diseases</i> , 2013, 16, 625-636.	0.9	34
82	Risks and outcomes of peritonitis after flexible colonoscopy in CAPD patients. <i>Peritoneal Dialysis International</i> , 2007, 27, 560-4.	1.1	33
83	Colonic Diverticulosis as a Risk Factor for Peritonitis in Chinese Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2010, 30, 187-191.	1.1	32
84	Dyslipidaemia in patients with lupus nephritis. <i>Nephrology</i> , 2011, 16, 511-517.	0.7	32
85	Noninvasive assessment of kidney allograft fibrosis with shear wave elastography: A radiological-pathological correlation analysis. <i>International Journal of Urology</i> , 2018, 25, 450-455.	0.5	30
86	Mesothelial cells. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S110-5.	1.1	30
87	Three SNPs in chromosome 11q23.3 are independently associated with systemic lupus erythematosus in Asians. <i>Human Molecular Genetics</i> , 2014, 23, 524-533.	1.4	29
88	Genome-wide search followed by replication reveals genetic interaction of <i>CD80</i> and <i>ALOX5AP</i> associated with systemic lupus erythematosus in Asian populations. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 891-898.	0.5	28
89	Molecular and Immunological Basis of Tubulo-Interstitial Injury in Lupus Nephritis: a Comprehensive Review. <i>Clinical Reviews in Allergy and Immunology</i> , 2017, 52, 149-163.	2.9	28
90	Direct and indirect costs of end-stage renal disease patients in the first and second years after initiation of nocturnal home haemodialysis, hospital haemodialysis and peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 1565-1576.	0.4	28

#	ARTICLE	IF	CITATIONS
91	Prospective Study on Lamivudine-Resistant Hepatitis B in Renal Allograft Recipients. <i>American Journal of Transplantation</i> , 2004, 4, 1103-1109.	2.6	26
92	Impact of a Low-Glucose Peritoneal Dialysis Regimen on Fibrosis and Inflammation Biomarkers. <i>Peritoneal Dialysis International</i> , 2015, 35, 147-158.	1.1	26
93	Binding of anti-dsDNA antibodies to proximal tubular epithelial cells contributes to renal tubulointerstitial inflammation. <i>Clinical Science</i> , 2017, 131, 49-67.	1.8	25
94	Lupus nephritis: An update on treatments and pathogenesis. <i>Nephrology</i> , 2018, 23, 80-83.	0.7	25
95	Distinct effects of mycophenolate mofetil and cyclophosphamide on renal fibrosis in NZBWF1/J mice. <i>Autoimmunity</i> , 2015, 48, 471-487.	1.2	24
96	Clinical Outcomes and Clinico-pathological Correlations in Lupus Nephritis with Kidney Biopsy Showing Thrombotic Microangiopathy. <i>Journal of Rheumatology</i> , 2019, 46, 1478-1484.	1.0	24
97	Vaccination in patients with chronic kidney disease—Review of current recommendations and recent advances. <i>Nephrology</i> , 2021, 26, 5-11.	0.7	24
98	Reduction of Perlecan Synthesis and Induction of TGF- β 1 in Human Peritoneal Mesothelial Cells Due to High Dialysate Glucose Concentration: Implication in Peritoneal Dialysis. <i>Journal of the American Society of Nephrology: JASN</i> , 2004, 15, 1178-1188.	3.0	23
99	Renal cell carcinoma of native kidney in Chinese renal transplant recipients: a report of 12 cases and a review of the literature. <i>International Urology and Nephrology</i> , 2011, 43, 675-680.	0.6	23
100	Prevalence of cognitive impairment among peritoneal dialysis patients: a systematic review and meta-analysis. <i>Clinical and Experimental Nephrology</i> , 2019, 23, 1221-1234.	0.7	22
101	Effect of mycophenolate and rapamycin on renal fibrosis in lupus nephritis. <i>Clinical Science</i> , 2019, 133, 1721-1744.	1.8	22
102	Pharmacokinetics and pharmacogenomics of mycophenolic acid and its clinical correlations in maintenance immunosuppression for lupus nephritis. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, 810-818.	0.4	22
103	Response to adefovir or entecavir in renal allograft recipients with hepatitis flare due to lamivudine-resistant hepatitis B. <i>Clinical Transplantation</i> , 2010, 24, 207-212.	0.8	21
104	The Role of Hyaluronan and CD44 in the Pathogenesis of Lupus Nephritis. <i>Autoimmune Diseases</i> , 2012, 2012, 1-9.	2.7	21
105	Recent advances in the understanding of renal inflammation and fibrosis in lupus nephritis. <i>F1000Research</i> , 2017, 6, 874.	0.8	21
106	Entecavir treatment in kidney transplant recipients infected with hepatitis B. <i>Clinical Transplantation</i> , 2014, 28, 1010-1015.	0.8	20
107	EFFICACY OF FAMCICLOVIR IN THE TREATMENT OF LAMIVUDINE RESISTANCE RELATED TO AN ATYPICAL HEPATITIS B VIRUS MUTANT. <i>Transplantation</i> , 2002, 73, 148-151.	0.5	20
108	Immunogenicity and Safety of COVID-19 Vaccines in Patients Receiving Renal Replacement Therapy: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 827859.	1.2	20

#	ARTICLE	IF	CITATIONS
109	Procalcitonin Fails to Differentiate Inflammatory Status or Predict Long-Term Outcomes in Peritoneal Dialysis-Associated Peritonitis. <i>Peritoneal Dialysis International</i> , 2008, 28, 377-384.	1.1	19
110	Diltiazem co-treatment in renal transplant patients receiving microemulsion cyclosporin. <i>British Journal of Clinical Pharmacology</i> , 2003, 56, 670-678.	1.1	18
111	Retroperitoneal Leakage as a Cause of Acute Ultrafiltration Failure: Its Associated Risk Factors in Peritoneal Dialysis. <i>Peritoneal Dialysis International</i> , 2009, 29, 542-547.	1.1	18
112	Rapamycin Attenuates the Severity of Murine Adriamycin Nephropathy. <i>American Journal of Nephrology</i> , 2009, 29, 342-352.	1.4	18
113	Serum and urinary biomarkers that predict hepatorenal syndrome in patients with advanced cirrhosis. <i>Digestive and Liver Disease</i> , 2017, 49, 202-206.	0.4	18
114	A Longitudinal Study on the Prevalence and Risk Factors for Depression and Anxiety, Quality of Life, and Clinical Outcomes in Incident Peritoneal Dialysis Patients. <i>Peritoneal Dialysis International</i> , 2019, 39, 74-82.	1.1	17
115	MicroRNAs in Lupus Nephritis—Role in Disease Pathogenesis and Clinical Applications. <i>International Journal of Molecular Sciences</i> , 2021, 22, 10737.	1.8	17
116	Preventing renal failure in patients with severe lupus nephritis. <i>Kidney International</i> , 2005, 67, S116-S119.	2.6	16
117	A Prospective Randomized Study Comparing Tenckhoff Catheters Inserted using the Triple Incision Method with Standard Swan Neck Catheters. <i>Peritoneal Dialysis International</i> , 2010, 30, 56-62.	1.1	16
118	Epistatic Interaction between Genetic Variants in Susceptibility Gene <i>ETS1</i> Correlates with IL-17 Levels in SLE Patients. <i>Annals of Human Genetics</i> , 2013, 77, 344-350.	0.3	16
119	A review of advances in the understanding of lupus nephritis pathogenesis as a basis for emerging therapies. <i>F1000Research</i> , 2020, 9, 905.	0.8	16
120	Evolution of hepatitis B management in kidney transplantation. <i>World Journal of Gastroenterology</i> , 2014, 20, 468.	1.4	16
121	Health-related quality of life and health utility of Chinese patients undergoing nocturnal home haemodialysis in comparison with other modes of dialysis. <i>Nephrology</i> , 2019, 24, 630-637.	0.7	15
122	Preemptive immunosuppressive treatment for asymptomatic serological reactivation may reduce renal flares in patients with lupus nephritis: a cohort study. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 467-473.	0.4	15
123	The Therapeutic Evaluation of Steroids in IgA Nephropathy Global (TESTING) Study: Trial Design and Baseline Characteristics. <i>American Journal of Nephrology</i> , 2021, 52, 827-836.	1.4	15
124	Glycosaminoglycans and proteoglycans: overlooked entities?. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S104-9.	1.1	15
125	Mannose binding lectin level and polymorphism in patients on long-term peritoneal dialysis. <i>Nephrology Dialysis Transplantation</i> , 2005, 20, 2489-2496.	0.4	14
126	Peritoneal Proteoglycans: Much more than Ground Substance. <i>Peritoneal Dialysis International</i> , 2007, 27, 375-390.	1.1	14

#	ARTICLE	IF	CITATIONS
127	Gene-Based Meta-Analysis of Genome-Wide Association Study Data Identifies Independent Single-Nucleotide Polymorphisms in <i>ANXA6</i> as Being Associated With Systemic Lupus Erythematosus in Asian Populations. <i>Arthritis and Rheumatology</i> , 2015, 67, 2966-2977.	2.9	14
128	Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2016, 32, 1097-1108.	0.9	14
129	Annexin II-binding immunoglobulins in patients with lupus nephritis and their correlation with disease manifestations. <i>Clinical Science</i> , 2017, 131, 653-671.	1.8	14
130	miR-200c Prevents TGF- β 1-Induced Epithelial-to-Mesenchymal Transition and Fibrogenesis in Mesothelial Cells by Targeting ZEB2 and Notch1. <i>Molecular Therapy - Nucleic Acids</i> , 2019, 17, 78-91.	2.3	14
131	Anti-fibrotic effect of decorin in peritoneal dialysis and PD-associated peritonitis. <i>EBioMedicine</i> , 2020, 52, 102661.	2.7	14
132	Clinico-pathological associations of serum VCAM-1 and ICAM-1 levels in patients with lupus nephritis. <i>Lupus</i> , 2021, 30, 1039-1050.	0.8	14
133	Serum immunoglobulin G level in patients with lupus nephritis and the effect of treatment with corticosteroids and mycophenolate mofetil. <i>Lupus</i> , 2014, 23, 678-683.	0.8	13
134	Developing the ethical framework of end-stage kidney disease care: from practice to policy. <i>Kidney International Supplements</i> , 2020, 10, e72-e77.	4.6	13
135	The role of kidney transplantation as a component of integrated care for chronic kidney disease. <i>Kidney International Supplements</i> , 2020, 10, e78-e85.	4.6	13
136	Lifetime cost-effectiveness analysis of first-line dialysis modalities for patients with end-stage renal disease under peritoneal dialysis first policy. <i>BMC Nephrology</i> , 2020, 21, 42.	0.8	13
137	Conversion of ciclosporin A to tacrolimus in kidney transplant recipients with chronic allograft nephropathy. <i>Nephrology Dialysis Transplantation</i> , 2006, 21, 3243-3251.	0.4	12
138	Histological reclassification of lupus nephritis. <i>Current Opinion in Nephrology and Hypertension</i> , 2005, 14, 561-566.	1.0	11
139	<i>Streptococcus Bovis</i> Peritonitis Complicating Peritoneal Dialysis—A Review of 10 Years' Experience. <i>Peritoneal Dialysis International</i> , 2012, 32, 55-59.	1.1	11
140	Treatment of lupus nephritis: practical issues in Asian countries. <i>International Journal of Rheumatic Diseases</i> , 2015, 18, 138-145.	0.9	11
141	Prevalence of hepatitis C virus infection in hemodialysis patients: A longitudinal study comparing the results of RNA and antibody assays. <i>Hepatology</i> , 1993, 17, 5-8.	3.6	11
142	Management of hepatitis B reactivation in patients with lupus nephritis. <i>Rheumatology International</i> , 2009, 29, 1273-1277.	1.5	10
143	Self-Care Peritoneal Dialysis Patients with Cognitive Impairment Have a Higher Risk of Peritonitis in the Second Year. <i>Peritoneal Dialysis International</i> , 2019, 39, 51-58.	1.1	10
144	Serum syndecan-1, hyaluronan and thrombomodulin levels in patients with lupus nephritis. <i>Rheumatology</i> , 2021, 60, 737-750.	0.9	10

#	ARTICLE	IF	CITATIONS
145	Demographics and long-term outcomes of children with end-stage kidney disease: A 20-year territory-wide study. <i>Nephrology</i> , 2022, 27, 171-180.	0.7	10
146	Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression. <i>Journal of the American Society of Nephrology: JASN</i> , 2022, 33, 291-303.	3.0	10
147	Significant reduction of Tacrolimus trough level after conversion from twice daily Prograf to once daily Advagraf in Chinese renal transplant recipients with or without concomitant diltiazem treatment. <i>Renal Failure</i> , 2013, 35, 942-945.	0.8	9
148	Serum level of proximal renal tubular epithelial cell-binding immunoglobulin G in patients with lupus nephritis. <i>Lupus</i> , 2016, 25, 46-53.	0.8	9
149	Long-Term Results of Triple Immunosuppression With Tacrolimus Added to Mycophenolate and Corticosteroids in the Treatment of Lupus Nephritis. <i>Kidney International Reports</i> , 2022, 7, 516-525.	0.4	9
150	B Cells in Primary Membranous Nephropathy: Escape from Immune Tolerance and Implications for Patient Management. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13560.	1.8	9
151	High Prevalence of Vitamin D Insufficiency in Southern Chinese Renal Transplant Recipients. <i>Renal Failure</i> , 2012, 34, 980-984.	0.8	8
152	New Onset Psoriasis after rituximab for Treatment of Idiopathic Membranous Nephropathy. <i>Nephrology</i> , 2014, 19, 60-60.	0.7	8
153	Palliative Care Consultation in Advanced Chronic Kidney Disease with Pain. <i>Journal of Palliative Medicine</i> , 2018, 21, 809-814.	0.6	8
154	Case of relapsing COVID-19 in a kidney transplant recipient. <i>Nephrology</i> , 2020, 25, 933-936.	0.7	8
155	B Cell Subsets and Cellular Signatures and Disease Relapse in Lupus Nephritis. <i>Frontiers in Immunology</i> , 2020, 11, 1732.	2.2	8
156	Studying the effects of new peritoneal dialysis solutions on the peritoneum. <i>Peritoneal Dialysis International</i> , 2007, 27 Suppl 2, S87-93.	1.1	8
157	INCREASED SURVIVAL OF MESOTHELIAL CELLS FROM THE PERITONEUM IN PERITONEAL DIALYSIS FLUID. <i>Cell Biology International</i> , 2001, 25, 445-450.	1.4	7
158	Tuberculous lymphadenitis in patients undergoing continuous ambulatory peritoneal dialysis. <i>International Urology and Nephrology</i> , 2007, 39, 971-974.	0.6	6
159	Recent Progress in the Treatment of Proliferative Lupus Nephritis. <i>American Journal of Medicine</i> , 2012, 125, 642-648.	0.6	6
160	<i>Burkholderia cepacia</i> "An Uncommon Cause of Exit-Site Infection in a Peritoneal Dialysis Patient. <i>Peritoneal Dialysis International</i> , 2014, 34, 471-472.	1.1	6
161	Meta-analysis of two Chinese populations identifies an autoimmune disease risk allele in 22q11.21 as associated with systemic lupus erythematosus. <i>Arthritis Research and Therapy</i> , 2015, 17, 67.	1.6	6
162	Peritoneal proteoglycans: much more than ground substance. <i>Peritoneal Dialysis International</i> , 2007, 27, 375-90.	1.1	6

#	ARTICLE	IF	CITATIONS
163	What is the ideal duration of maintenance therapy for lupus nephritis?. Expert Review of Clinical Immunology, 2022, 18, 425-427.	1.3	6
164	Correlation study between spot urine protein-to-creatinine ratio and 24-hour urine protein measurement in 174 patients for proteinuria assessment. Hong Kong Journal of Nephrology, 2011, 13, 51-54.	0.0	5
165	<i>Burkholderia Cepacia</i> Exit-Site Infection in Peritoneal Dialysis Patientsâ€”Clinical Characteristics and Treatment Outcomes. Peritoneal Dialysis International, 2016, 36, 390-394.	1.1	5
166	TRANSHEPATIC PLACEMENT OF HAEMODIALYSIS CATHETER: A SOLUTION FOR VASCULAR ACCESS EXHAUSTION. Nephrology, 2010, 15, 661-662.	0.7	4
167	Dialysis practice from the English NHS to the orient. CKJ: Clinical Kidney Journal, 2013, 6, 554-555.	1.4	4
168	Arthrobacter sanguinis: An uncommon cause of peritonitis in a peritoneal dialysis patient. Nephrology, 2015, 20, 868-868.	0.7	4
169	Predictive value of plasma neutrophil gelatinase-associated lipocalin for acute kidney injury in intensive care unit patients after major nonâ€œcardiac surgery. Nephrology, 2015, 20, 375-382.	0.7	4
170	Severe liver failure due to influenza A infection in a hemodialysis patient. Hemodialysis International, 2016, 20, E16-8.	0.4	4
171	Use of telbivudine in kidney transplant recipients with chronic hepatitis B virus infection: A preliminary experience. Nephrology, 2016, 21, 438-441.	0.7	4
172	Long-term data on entecavir treatment for treatment-naïve or lamivudine-resistant chronic hepatitis B infection in kidney transplant recipients. Transplant Infectious Disease, 2019, 21, e13143.	0.7	4
173	Mesangial Cell-Binding Activity of Serum Immunoglobulin G in Patients with Lupus Nephritis. PLoS ONE, 2014, 9, e101987.	1.1	4
174	Treatment of acute kidney injury complicating septic shock with EMIC2 high-cutoff hemofilter: Case series. Indian Journal of Critical Care Medicine, 2017, 21, 751-757.	0.3	4
175	An Unusual Organism for PD-Related Peritonitis: <i>Hafnia Alvei</i> . Peritoneal Dialysis International, 2010, 30, 254-255.	1.1	3
176	Renal allograft tissue: its new role in patient management. Histopathology, 2012, 60, 1160-1162.	1.6	3
177	Successful Treatment of Pulmonary <i>Rhizopus</i> Infection with Surgical Resection and Posaconazole in a Renal Transplant Recipient. Nephrology, 2013, 18, 74-75.	0.7	3
178	Cortical necrosis in a kidney transplant recipient due to leptospirosis. Nephrology, 2014, 19, 257-258.	0.7	3
179	Chronotropic incompetence, echocardiographic abnormalities and exercise intolerance in renal transplant recipients. Journal of Nephrology, 2014, 27, 451-456.	0.9	3
180	Acute Phosphate Nephropathy: An Under-Recognized Complication Leading to Impaired Allograft Function After Renal Transplant. Nephrology, 2016, 21, 980-981.	0.7	3

#	ARTICLE	IF	CITATIONS
181	Acute kidney injury in a renal transplant recipient due to concomitant use of vancomycin and foscarnet. <i>Nephrology</i> , 2017, 22, 821-822.	0.7	3
182	Effect of Combined Mycophenolate and Rapamycin Treatment on Kidney Fibrosis in Murine Lupus Nephritis. <i>Frontiers in Pharmacology</i> , 2022, 13, 866077.	1.6	3
183	PERINEPHRIC HEMATOMA AND MASSIVE GASTROINTESTINAL HEMORRHAGE (GIB) COMPLICATING POLYARTERITIS NODOSA (PAN). <i>Renal Failure</i> , 2000, 22, 379-384.	0.8	2
184	Histologic deterioration and more flares: The case against azathioprine plus methylprednisolone in the treatment of proliferative lupus nephritis. <i>Arthritis and Rheumatism</i> , 2007, 56, 702-704.	6.7	2
185	Lupus Nephritis—An Enriching Opus. <i>Hong Kong Journal of Nephrology</i> , 2009, 11, 5-8.	0.0	2
186	Dosing regimen and tolerability of methoxy polyethylene glycol—epoetin beta in Chinese dialysis patients. <i>Nephrology</i> , 2013, 18, 533-538.	0.7	2
187	Epistaxis in a kidney transplant recipient: An uncommon presentation of post-transplant lymphoproliferative disease. <i>Nephrology</i> , 2013, 18, 531-531.	0.7	2
188	Invasive fungal rhinosinusitis presenting as Bell's palsy in a kidney and liver transplant recipient. <i>Journal of the Formosan Medical Association</i> , 2017, 116, 910-911.	0.8	2
189	Tissue Remodeling and Inflammation during Peritoneal Dialysis: Catheter versus Fluid. <i>Peritoneal Dialysis International</i> , 2010, 30, 274-276.	1.1	1
190	Severe hypocalcaemia and hyperphosphataemia caused by oral sodium phosphate fleet solution in a haemodialysis patient after parathyroidectomy. <i>CKJ: Clinical Kidney Journal</i> , 2011, 4, 248-250.	1.4	1
191	Kidney Allograft Abscess: An Unusual Cause of Peritonitis in a Patient on Peritoneal Dialysis. <i>Nephrology</i> , 2016, 21, 266-266.	0.7	1
192	In Vitro and In Vivo Renoprotective Effects of Telbivudine in Chronic Hepatitis B Patients Receiving Nucleotide Analogue. <i>Digestive Diseases and Sciences</i> , 2019, 64, 3630-3641.	1.1	1
193	Determinants of patient survival in systemic lupus erythematosus—focusing on lupus nephritis. <i>Ethnicity and Disease</i> , 2006, 16, S2-66-9.	1.0	1
194	Mycophenolate mofetil as treatment for lupus nephritis. <i>APLAR Journal of Rheumatology</i> , 2004, 7, 268-271.	0.2	0
195	Mycophenolate mofetil in the treatment of lupus nephritis: an appraisal of recent data. <i>APLAR Journal of Rheumatology</i> , 2006, 9, 403-407.	0.2	0
196	Emodin ameliorates glucose-induced fibronectin synthesis in human peritoneal mesothelial cells by inhibiting PKC α activation. <i>International Journal of Experimental Pathology</i> , 2004, 85, A15.	0.6	0
197	Peritoneal fibrosis and the putative role of decorin. <i>Hong Kong Journal of Nephrology</i> , 2013, 15, 55-61.	0.0	0
198	An overview of current and future treatment methods for lupus nephritis. <i>Expert Opinion on Orphan Drugs</i> , 2014, 2, 169-179.	0.5	0

#	ARTICLE	IF	CITATIONS
199	Antiviral treatment for chronic hepatitis B infection in renal transplant recipients. Hong Kong Journal of Nephrology, 2015, 17, 8-13.	0.0	0
200	SP165RISK FACTORS FOR RENAL FLARES IN LUPUS NEPHRITIS AND THE IMPACT OF MYCOPHENOLIC ACID TREATMENT ON RELAPSE. Nephrology Dialysis Transplantation, 2016, 31, i140-i141.	0.4	0
201	MP122THE IMPACT OF PRE-EMPTIVE INCREASE IN IMMUNOSUPPRESSIVE TREATMENTS ON SUBSEQUENT RISK OF RENAL FLARES IN LUPUS NEPHRITIS PATIENTS. Nephrology Dialysis Transplantation, 2016, 31, i383-i383.	0.4	0
202	Secondary atypical mycobacterial infection after peritoneal catheter removal. International Wound Journal, 2016, 13, 1021-1022.	1.3	0
203	Risk factors and prognosis of late acute rejection in Chinese kidney transplant recipients. Nephrology, 2017, 22, 985-992.	0.7	0
204	SaO017ANTIPHOSPHOLIPID ANTIBODIES IN LUPUS NEPHRITIS - A SINGLE CENTRE EXPERIENCE. Nephrology Dialysis Transplantation, 2018, 33, i322-i322.	0.4	0
205	FP165CLINICAL CHARACTERISTICS AND OUTCOMES OF LUPUS NEPHRITIS PATIENTS WITH KIDNEY BIOPSY SHOWING THROMBOTIC MICROANGIOPATHY. Nephrology Dialysis Transplantation, 2018, 33, i85-i85.	0.4	0
206	Clinical practice guidelines for the provision of renal service in Hong Kong: Infection Control in Renal Service. Nephrology, 2019, 24, 98-129.	0.7	0
207	P1198CATHETER-RELATED INFECTIONS DUE TO SERRATIA SPECIES IN PATIENTS RECEIVING PERITONEAL DIALYSIS. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
208	SO077A PROSPECTIVE RANDOMIZED STUDY ON PRE-EMPTIVE IMMUNOSUPPRESSIVE TREATMENT IN LUPUS NEPHRITIS PATIENTS WITH ASYMPTOMATIC SEROLOGICAL REACTIVATION. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
209	Conversion from Aranesp® to NESP Â® in dialysis patientsâ€™Exploration of dosing strategies and the feasibility of extending the dosing interval. Nephrology, 2021, 26, 733-741.	0.7	0